## Eli Lilly Co. Posts $2.3B Q4 Profit, $31.15B 2023 Sales Guidance ### Pharmaceutical giant Eli Lilly and Company (NYSE: LLY) posted a profitable fourth quarter, driven by strong sales of its diabetes and immunology drugs. - The company reported a net income of $2.3 billion, or $2.16 per share, for the three months ending Dec. 31, 2022. - This represents a 10% increase from the $2.1 billion, or $1.96 per share, earned in the same period of 2021. - Revenue during the quarter climbed 7% to $7.3 billion, boosted by higher sales of Trulicity, a diabetes drug, and Taltz, a medication used to treat psoriasis and psoriatic arthritis. ### Lilly's Full-Year Results and 2023 Outlook - For the full year 2022, Lilly reported net income of $8.4 billion, or $7.76 per share, on revenue of $28.3 billion. - The company expects to achieve revenue of $31.15 billion in 2023, reflecting an increase of approximately 10%. - Lilly also anticipates adjusted earnings per share to be in the range of $8.75 to $8.95. ### Key Drug Performance - Trulicity sales increased 11% to $1.9 billion in the fourth quarter, while for the full year, sales reached $7.3 billion, a 16% increase. - Taltz sales rose 14% to $653 million in the fourth quarter and totaled $2.4 billion for the full year, representing a 17% growth. - Jardiance, a type 2 diabetes drug, generated sales of $575 million in the fourth quarter, a 13% increase.
